John J Alam
6PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Nov 10, 2023
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.John J Alam, Ralph A Nixon
|Oct 04, 2023
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.John J Alam, Ralph A Nixon
|Sep 01, 2023
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.John J Alam, Paul Maruff, Susan R Doctrow
|Sep 21, 2022
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.Ying Jiang, John J Alam, Stephen N Gomperts
|Aug 14, 2021
Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration.John J Alam, Ralph A Nixon
|Dec 04, 2020
Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.John J Alam, Michael Krakovsky, Ursula Germann
Pageof 1
